This provides full disease control: intravenous SPEVIGO treats GPP flares, while subcutaneous SPEVIGO prevents them. 5 ...

In a move aimed to provide relief to patients battling severe chronic ailments Union Finance Minister Nirmala Sitharaman on Saturday announced the expansion of ...

New Delhi: Finance Minister Nirmala Sitharaman announced a full exemption from basic customs duty (BCD) for 36 live-saving ...

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] Draft guidance Technology appraisal guidance 25 February 2025 Tarlatamab for previously treated ...

Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new ...

Customs duty exemption in Budget for cancer drugs, rare diseases including SMA: Our Bureau, New Delhi Saturday, February 1, 2025, 15:20 Hrs [IST] The 36 life saving drugs and medi ...

Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] Draft guidance Technology appraisal guidance 18 February 2025 Spesolimab for treating generalised pustular psoriasis flares ...

Treatments for rare diseases like Risdiplam, Spesolimab, Velaglucerase Alpha, and Agalsidase Alfa have also been included. Additionally, medicines for severe chronic illnesses such as Alirocumab ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

Drugs like Inclisiran (cholesterol management) by Novartis and Spesolimab (inflammatory diseases) by GSK will also see reduced prices, making long-term treatments more affordable for patients.